You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股表現》賽生藥業(06600.HK)暗盤高開6.4%報20元
阿思達克 03-02 16:15
根據輝立交易平台顯示,明天掛牌的賽生藥業(06600.HK)暗盤高開6.4%報20元暫欠承接,最低見18.8元,現造19元,較上市價18.8元,高1.1%,成交22萬股。

賽生藥業是一家擁有產品開發和商業化集成平台的生物製藥公司,其戰略上專注於內地一些最大且發展迅速存在重大未滿足醫療需求的治療領域,主要包括腫瘤及重症感染。 公司也力圖在重點治療領域開發優質上市產品(包括自有產品日達仙)及在研藥物組合並對其進行商業化。

賽生是次來港上市共發售近1.16億股,並已引入包括Shanghai Pharmaceutical Lin-gang Special Area、Daguan International、China Post and Capital Global Asset Management等11名基石投資者,合共認購5,513萬股(設6個月禁售期);其中10%公開發售獲1,067倍超購,已啟動回撥機制佔比增至50%,認購一手中籤率僅3%;股份以招股範圍(17.2-18.8元)上限定價,料集資淨額約20.4億元,主要用於投資內地或其他全球市場潛在藥物收購和授權、還債、用作開發和商業化臨床階段候選產品、招聘與擴大銷售網絡及商業和開發基礎設施、為持續臨床研究提供資金。上市聯席保薦人分別為大摩、中金及瑞信。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account